摘要
目的:探讨乳腺癌患者手术或化疗后血清HER-2/neuECD水平变化的临床意义。方法:双抗体夹心ELISA法检测早期乳腺癌患者及其配对手术、化疗前后血清HER-2/neuECD水平,进行统计分析。结果:82例乳腺癌患者手术后,血清HER-2/neuECD水平90.24%(74/82)下降,3.66%(3/82,C.V≤5%)未变化,6.10%(5/82)升高;46例乳腺癌患者化疗后HER-2/neuECD水平升高组(15/46)对化疗的反应率73.33%(11/15)与HER-2/neuECD水平非升高组(HER-2/neuECD水平下降或不变,C.V≤5%,31/46)对化疗的反应率77.42%(24/31)无差别(P>0.05)。结论:检测乳腺癌患者血清HER-2/neuECD水平变化对预后可能具有一定的临床提示意义。
Objective： To evaluate the clinical implication of variations in serum HER-2/neu extracellular domain （ECD） level before and after treatment of primary breast cancer patients. Methods： Sera from breast cancer patients before and after surgery or chemotherapy were assayed by a HER-2/ neu ECD enzyme-linked immunosorbent assay （ELISA）. Results： The amount of serum HER-2/neu ECD was decreased in 74 patients （90.24%,74/82）, was steady in 3 patients （3.66%, 3/82, C.V≤5%） and was increased in 5 patients （6.10 %, 5/82） after surgery. 73.3% （11/15） of patients with increasing levels of her-2/neu ECD （15/46） and 77.42% （24/31） of patients with non-increasing levels of her-2/ neu ECD （17 were decreased and 7 were unchanged, C.V≤5%） responded to chemotherapy （CR and PR）（P 〉 0.05）, showing no difference between the two groups. Conclusion： Longitudinal monitoring of serum HER-2/neu ECD level changes may represent a valuable tool for predicting pathological response to treatment and prognosis in patients with breast cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2006年第13期728-730,共3页
Chinese Journal of Clinical Oncology
基金
首都发展基金科研项目资助(编号:2002-2023)
